Lista de obras -

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors ⬇️

artículo científico publicado el 17 de noviembre de 2012

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer

artículo científico publicado en 2017

A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours

artículo científico publicado en 2010

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

artículo científico publicado en 2008

A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors

artículo científico publicado en 2004

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

artículo científico publicado en 2014

A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma

artículo científico publicado en 2007

A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies.

artículo científico publicado en 2014

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

artículo científico publicado en 2004

Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human.

artículo científico publicado en 2017

BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer

artículo científico publicado en 2016

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors ⬇️

artículo científico publicado el 5 de octubre de 2011

CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.

artículo científico publicado en 2013

Chemoprevention in Patients with Peutz-Jeghers Syndrome: Lessons Learned

artículo científico publicado en 2018

Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study design

artículo científico publicado en 2000

Clinical trial design for target specific anticancer agents

artículo científico publicado en 2003

Critical assessment of angiogenesis inhibitors in clinical trials

artículo científico publicado en 2002

Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept

artículo científico publicado en 2013

Developments in chemotherapy; cytostatic agents with an increased specificity and other forms of administering cytotoxic antineoplastic agents

artículo científico publicado el 17 de noviembre de 2001

Differentiation and definition of vascular-targeted therapies.

artículo científico publicado en 2005

Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.

artículo científico publicado en 2002

Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor.

artículo científico publicado en 2000

Evaluation of patient enrollment in oncology phase I clinical trials.

artículo científico publicado en 2013

FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study

Farnesyl transferase inhibitors: current developments and future perspectives

artículo científico publicado en 2000

Improvement of 5 year survival rate after liver resection for colorectal metastases between 1984-2006

artículo científico publicado en 2009

Increased alpha-fetoprotein serum level is predictive for survival and recurrence of hepatocellular carcinoma in non-cirrhotic livers

artículo científico publicado en 2012

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

artículo científico publicado en 2014

Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.

artículo científico publicado en 2009

Matrix Metalloproteinase Inhibitors: Current Developments and Future Perspectives ⬇️

artículo científico publicado el 1 de enero de 2001

Moving molecular targeted drug therapy towards personalized medicine: Issues related to clinical trial design ⬇️

artículo científico publicado el 16 de febrero de 2012

Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial

artículo científico publicado en 2015

Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study

artículo científico publicado en 2013

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors

artículo científico publicado en 2009

Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.

artículo científico publicado en 2005

Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor

artículo científico publicado en 2004

Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors

artículo científico publicado en 2005

Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors

artículo científico publicado en 2001

Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer

artículo científico publicado en 2004

Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

artículo científico publicado en 2005

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours ⬇️

artículo científico publicado el 7 de septiembre de 2010

Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group

artículo científico publicado en 2000

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

artículo científico publicado en 2009

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

artículo científico publicado en 2014

Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors

artículo científico publicado en 2009

Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.

artículo científico publicado en 2013

Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors

artículo científico publicado en 2005

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

artículo científico publicado en 2009

Phase II study of weekly dose-intensified cisplatin chemotherapy with oral etoposide in recurrent glioma.

artículo científico publicado en 1999

Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study

artículo científico publicado en 2006

Protocol for the STRONG trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma, a phase I feasibility study

scientific article published on 15 October 2018

Sorafenib Induced Thyroiditis in Two Patients with Hepatocellular Carcinoma ⬇️

artículo científico publicado el 1 de febrero de 2011

Structure, Development, Preclinical and Clinical Efficacy of Tivozanib (KRN-951, AV-951) ⬇️

artículo científico publicado el 1 de enero de 2013

Systemic treatment in hepatocellular carcinoma; 'A small step for man...'.

artículo científico publicado en 2009

Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma.

artículo científico publicado en 2018

The addition of pravastatin to chemotherapy in advanced gastric carcinoma: A randomised phase II trial ⬇️

artículo científico publicado el 18 de agosto de 2010

The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation

artículo científico publicado en 2015

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review

artículo científico publicado en 2006

The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?

artículo científico publicado en 2008

Vascular disrupting agents in clinical development

artículo científico publicado en 2007

Lista de obras de

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors ⬇️

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer

A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma

A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies.

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human.

BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors ⬇️

CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.

Chemoprevention in Patients with Peutz-Jeghers Syndrome: Lessons Learned

Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study design

Clinical trial design for target specific anticancer agents

Critical assessment of angiogenesis inhibitors in clinical trials

Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept

Developments in chemotherapy; cytostatic agents with an increased specificity and other forms of administering cytotoxic antineoplastic agents

Differentiation and definition of vascular-targeted therapies.

Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.

Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor.

Evaluation of patient enrollment in oncology phase I clinical trials.

FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study

Farnesyl transferase inhibitors: current developments and future perspectives

Improvement of 5 year survival rate after liver resection for colorectal metastases between 1984-2006

Increased alpha-fetoprotein serum level is predictive for survival and recurrence of hepatocellular carcinoma in non-cirrhotic livers

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.

Matrix Metalloproteinase Inhibitors: Current Developments and Future Perspectives ⬇️

Moving molecular targeted drug therapy towards personalized medicine: Issues related to clinical trial design ⬇️

Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial

Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors

Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.

Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor

Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors

Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors

Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer

Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours ⬇️

Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors

Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.

Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

Phase II study of weekly dose-intensified cisplatin chemotherapy with oral etoposide in recurrent glioma.

Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study

Protocol for the STRONG trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma, a phase I feasibility study

Sorafenib Induced Thyroiditis in Two Patients with Hepatocellular Carcinoma ⬇️

Structure, Development, Preclinical and Clinical Efficacy of Tivozanib (KRN-951, AV-951) ⬇️

Systemic treatment in hepatocellular carcinoma; 'A small step for man...'.

Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma.

The addition of pravastatin to chemotherapy in advanced gastric carcinoma: A randomised phase II trial ⬇️

The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review

The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?

Vascular disrupting agents in clinical development